RECK

Across TCGA pan-cancer cohorts, RECK mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RECK data layer compared with 28 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RECK mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RECK expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where RECK mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	III,IV	0.947	0.760	.011	8	view →
LSCC	DFS	Quartile	II,III,IV	0.397	0.919	.007	7	view →
LUAD	OS	Median	II,III,IV	0.862	1.000	.004	4	view →
CCRCC	OS	Median	II,III,IV	0.385	1.000	.042	2	view →
PDAC	DFS	Median	II,III,IV	0.336	0.444	.049	2	view →
GBM	DFS	Median	All	0.666	0.836	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RECK–HNSC (OS)

Open the HNSC breakdown →